Q-omics provides the consensus-scored RAVER1 profile across patient tissues and cancer cell-line models. RAVER1 expression is associated with patient survival in 25 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, RAVER1 is differentially expressed in 14, with the highest sampling consensus in HNSC. Additionally, RAVER1 protein abundance shows 24,430 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight HNSC, and GBM as cancer lineages where RAVER1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RAVER1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RAVER1 survival associations across molecular data types. RAVER1 RNA expression shows survival associations in the most cancer types (25), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RAVER1 RNA expression–survival associations across cancer types. High RAVER1 expression shows unfavorable associations in ACC and LGG, but favorable associations in HNSC, SCLC, KIRC and UCS. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .001). Together, the overview and detailed table identify HNSC as the clearest survival context for RAVER1 RNA expression.
This table summarizes RAVER1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in HNSC for RNA and CCRCC for protein.
This table ranks reproducible tumor–normal expression differences for RAVER1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RAVER1 shows higher tumor expression in HNSC, KIRP, BLCA, STAD, COAD and KIRC. The HNSC box plot shows higher RAVER1 RNA expression in tumor versus normal tissue (log2 FC = +1.255, t-test p < 0.001).
This table shows molecular features associated with RAVER1 in patient tissues and cancer cell lines. In patient samples, RAVER1 shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, RAVER1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in UPPER_AERODIGESTIVE_TRACT, while CRISPR and shRNA rows add functional-dependency signals in BREAST and BLOOD_Leukemia.
